United Therapeutics Corporation Proceeds from Sale of Debt Securities, Available-for-sale
United Therapeutics Corporation (UTHR) reported Proceeds from Sale of Debt Securities, Available-for-sale of $1.31 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt · last filed 2026-08-05
- United Therapeutics Corporation proceeds from sale of debt securities, available-for-sale for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- United Therapeutics Corporation proceeds from sale of debt securities, available-for-sale for the quarter ending 2026-03-31 was $1.31B.
- United Therapeutics Corporation proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00.
- United Therapeutics Corporation proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-09-30 was $596.00M.
- United Therapeutics Corporation proceeds from sale of debt securities, available-for-sale for fiscal 2025 was $1.86B, a 123.80% increase from fiscal 2024.
- United Therapeutics Corporation proceeds from sale of debt securities, available-for-sale for fiscal 2024 was $831.80M.
- United Therapeutics Corporation proceeds from sale of debt securities, available-for-sale for fiscal 2023 was $0.00.
- United Therapeutics Corporation proceeds from sale of debt securities, available-for-sale for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Proceeds from Sale of Debt Securities, Available-for-sale 3 month | Proceeds from Sale of Debt Securities, Available-for-sale 6 month | Proceeds from Sale of Debt Securities, Available-for-sale 9 month | Proceeds from Sale of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.31B 10-Q · filed 2026-08-05 | $1.31B derived: sum of 3 quarters · filed 2026-08-05 | $1.90B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.31B 10-Q · filed 2026-05-06 | $1.31B derived: sum of 2 quarters · filed 2026-05-06 | $1.90B derived: sum of 3 quarters · filed 2026-05-06 | $3.17B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $596.00M derived: sum of 2 quarters · filed 2026-02-25 | $1.86B derived: sum of 3 quarters · filed 2026-08-05 | $1.86B 10-K · filed 2026-02-25 |
| 2025-09-30 | $596.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $1.86B derived: sum of 2 quarters · filed 2026-08-05 | $1.86B 10-Q · filed 2025-10-29 | $1.86B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.27B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.27B 10-Q · filed 2026-08-05 | $1.27B derived: sum of 3 quarters · filed 2026-08-05 | $1.27B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $0.00 derived: sum of 3 quarters · filed 2026-05-06 | $0.00 derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $831.80M 10-K · filed 2026-02-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $0.00 derived: sum of 2 quarters · filed 2025-10-29 | $831.80M 10-Q · filed 2025-10-29 | $831.80M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $831.80M 10-Q · filed 2025-07-30 | $831.80M derived: sum of 3 quarters · filed 2026-02-25 | $831.80M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $831.80M 10-Q · filed 2025-04-30 | $831.80M derived: sum of 2 quarters · filed 2026-02-25 | $831.80M derived: sum of 3 quarters · filed 2026-02-25 | $831.80M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $0.00 derived: sum of 2 quarters · filed 2024-10-30 | $0.00 10-Q · filed 2024-10-30 | $0.00 derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $0.00 10-Q · filed 2024-07-31 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-01 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 10-K · filed 2025-02-26 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 10-Q · filed 2022-11-02 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-03 | |||
| 2021-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $2.50M derived: sum of 2 quarters · filed 2024-02-21 | $47.60M derived: sum of 3 quarters · filed 2024-02-21 | $47.60M 10-K · filed 2024-02-21 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $45.10M derived: sum of 2 quarters · filed 2022-11-02 | $45.10M 10-Q · filed 2022-11-02 | $45.10M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $45.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $45.10M 10-Q · filed 2022-08-03 | $45.10M derived: sum of 3 quarters · filed 2023-02-22 | $62.70M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-05 | $0.00 derived: sum of 2 quarters · filed 2023-02-22 | $17.60M derived: sum of 3 quarters · filed 2023-02-22 | $60.50M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $17.60M derived: sum of 2 quarters · filed 2023-02-22 | $60.50M derived: sum of 3 quarters · filed 2023-02-22 | $76.50M 10-K · filed 2023-02-22 |
| 2020-09-30 | $17.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $60.50M derived: sum of 2 quarters · filed 2021-11-03 | $76.50M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $42.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $58.90M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $16.00M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $180.90M 10-K · filed 2022-02-24 | |||
| 2018-12-31 | $46.40M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |